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 Chapter 20 
 NCI-H716 Cells 
 Jeffrey  Gagnon and  Patricia  L.  Brubaker 
 Abstract  The endocrine response to nutrient ingestion is vital to the maintenance 
of energy homeostasis in the body. Glucagon like peptide-1 (GLP-1) is one such 
hormone that is released from L-cells of the distal small intestine and colon in 
response to meal ingestion. GLP-1 acts on various systems in the body to enhance 
glucose-stimulated insulin secretion, delay gastric emptying and promote satiety. 
As such, elevating the levels of active GLP-1 in the circulation, as well as enhanc-
ing GLP-1 bioactivity, is the basis of several recent anti-diabetic medications. 
Gaining an understanding of how GLP-1 secretion is regulated at the cellular level 
requires in vitro L-cell models. NCI-H716 is a cell line derived from ascites fl uid of 
a colorectal adenocarcinoma from a 33 year old Caucasian male. This cell line is 
 currently the only human model available for the in vitro study of GLP-1 regulation 
and is the topic of the following chapter. This chapter will cover the origin, charac-
teristics and methods for using this model. Comparisons are then made between 
other available in vitro GLP-1 models. 
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20.1  Introduction 
 Glucagon like peptide 1 (GLP-1) is a key hormone in the regulation of nutrient 
metabolism. Its release from intestinal enteroendocrine L-cells is stimulated by the 
ingestion of nutrients (both directly, through luminal nutrient sensing, and indirectly, 
via parasympathetic innervation). The L-cells are distributed primarily in the distal 
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small intestine and colon. Once released into the circulation, GLP-1 acts to promote 
satiety as well as the storage of ingested nutrients. A well-established and pharma-
cologically-targeted aspect of GLP-1 action is its role in potentiating glucose- 
stimulated insulin secretion from the β cells of the pancreas. This action creates a 
larger insulin response to ingested glucose as compared to isoglycemic levels of 
glucose delivered intravenously, and is known as the incretin effect. The GLP-1 
responses to various dietary nutrients and their respective intracellular mechanisms 
of action on the L-cell have been, and continue to be, intensively studied using 
in vitro GLP-1-secreting cell models. One such model is the human colonic cell 
line, NCI-H716. This review will describe the origin, utility and associated methods 
of use of this cell line in the study of GLP-1 biology. 
20.2  Origin 
 NCI-H716 cells were one of several colorectal cancer cell lines originally described 
in 1987 (Park et al.  1987 ). This particular cell line was developed from cells har-
vested in ascites fl uid of a 33-year old Caucasian male with colorectal cancer. 
Interestingly, of the 14 cell lines described in this study, NCI-H716 was the only line 
that contained dense-core granules, which are characteristic of endocrine cells. 
While it was unclear as to the contents in these granules at the time of discovery, 
later work in several laboratories elucidated the hormones produced by these cells. 
Early studies with these cells demonstrated the expression of both the secretory 
granule marker, chromogranin A, and mucin, as well as receptors for gastrin, soma-
tostatin and serotonin (de Bruine et al.  1992 ). This not only confi rmed that these 
cells had an endocrine phenotype but suggested that they were also sensitive to 
other gastrointestinal hormones. After several years of being used as model of 
tumour/endocrine differentiation, Reimer et al. demonstrated both expression and 
regulated secretion of glucagon-like peptide-1 (GLP-1) by these cells (Reimer et al. 
 2001 ). In that study, NCI-H716 cells were found to secrete high levels of active 
GLP-1 in amounts that could be easily measured by collecting cell culture medium 
and cell lysates. They also showed that nutrients, including fatty acids and protein 
hydrolysate, dose-dependently stimulated GLP-1 secretion by these cells (Reimer 
et al.  2001 ). Following this, work by our group elucidated roles for several hor-
mones (Anini and Brubaker  2003b ; Lim et al.  2009 ), neurotransmitters (Anini and 
Brubaker  2003a ), fatty acids (Lauffer et al.  2009 ) and anti-diabetic medications 
(Mulherin et al.  2011 ) in the regulation of GLP-1 secretion. To date, the NCI-H716 
cells remain the only characterized model of the human intestinal L-cell. 
20.3  Features and Mechanisms 
 NCI-H716 cells are considered pseudo-diploid with an average chromosome count 
of 61 (Park et al.  1987 ). Electron micrographs shown in this initial study clearly 
demonstrate many dense-core granules. In culture, these cells appear spherical and 
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undifferentiated, and they grow in suspension, occasionally forming clumps. 
Plating the cells on a basement membrane-coated surface allows the cells to attach 
and grow horizontally. Although this plating strategy was initially reported to allow 
the cells to become differentiated towards an endocrine lineage (Reimer et al. 
 2001 ), studies by our laboratory and other groups have indicated that plating does 
not change the levels of GLP-1 in these cells (Anini and Brubaker  2003a ; Cao et al. 
 2003 ). 
 Anini and Brubaker demonstrated expression of the leptin receptor in NCI-H716 
cells by western blot and fl uorescent immunocytochemistry (Anini and Brubaker 
 2003b ). This study further showed that leptin stimulates GLP-1 secretion by these 
cells, and that the hyperleptinemia that occurs during obesity leads to leptin resis-
tance and impaired GLP-1 secretion in this condition. In that same year, Anini and 
Brubaker also demonstrated expression of the M1, M2 and M3 muscarinic receptors 
in the NCI-H716 cells by western blot and fl uorescent immunocytochemistry (Anini 
and Brubaker  2003a ). Herein, they also established a role for M1 muscarinic regula-
tion of GLP-1 secretion. Shortly after, Lim et al. showed that NCI-H716 cells express 
the insulin receptor, by semi-quantitative reverse transcriptase PCR and fl uorescent 
immunocytochemistry (Lim et al.  2009 ). They further demonstrated that, while insulin 
was able to stimulate GLP-1 secretion acutely, extended pre- incubation with insulin 
led to a loss in the ability of these cells to respond to other GLP-1 secretagogues. 
Hence, the hyperinsulinemia that occurs in patients with type 2 diabetes mellitus 
(T2DM) may also result in impaired GLP-1 secretion. 
 The ability of the L-cell to respond to luminal nutrients is a vital component of 
the incretin system. GLP-1 regulation by ingested nutrients through specifi c recep-
tors has been demonstrated using the NCI-H716 cell line. In the initial NCI-H716 
and GLP-1 secretion study, the authors showed that meat hydrolysate stimulated 
GLP-1 release (Reimer et al.  2001 ). Several years later, they also demonstrated 
mRNA expression of several amino acid transporters by these cells, including 
Y + LAT2, ASCT2, and ATA-2 (Reimer  2006 ). 
 Luminal glucose sensing by the L-cells has also been demonstrated through the 
sweet taste receptor system. NCI-H716 cells express several of the type 1 taste 
receptors and α-gustducin, which is a key component of the taste transduction 
pathway (Jang et al.  2007 ). In this study, knockdown of α-gustducin prevented the 
glucose- stimulated GLP-1 response by NCI-H716 cells. While this study and others 
(Zhang et al.  2012 ) have demonstrated that glucose can stimulate GLP-1 secretion 
from NCI-H716 cells, the presence of a glucose transporter has yet to be 
demonstrated. 
 Lipid sensing by the NCI-H716 cell line has been demonstrated by several 
groups (Chen et al.  2012 ; Lauffer et al.  2009 ). Expression of the monoacylglycerol- 
sensing G-protein coupled receptor, GPR119, by RT-PCR in NCI-H716 cells was 
shown by Lauffer et al. ( 2009 ). While examining the effects of milk products on 
GLP-1 secretion, Chen et al. also demonstrated expression of fatty acid transport 
protein 4 in the NCI-H716 cells by quantitative RT-PCR (Chen and Reimer  2009 ). 
 The above studies clearly indicate that NCI-H716 cells possess many of the 
receptors and intracellular machinery required to sense hormones, neurotransmitters 
and nutrients, and to release GLP-1 in response to these agents. 
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20.4  Stability/Consistency/Reproducibility 
 The increasing use of the NCI-H716 cells as a model of the human intestinal L-cell 
necessitates an examination of the consistency of fi ndings between different research 
groups using these cells. In terms of GLP-1 secretion, many groups now present 
secretion data relative to an untreated control, making interpretation of actual percent 
secretion diffi cult. However, early studies with the NCI-H716 cells demonstrated 
percent secretion to be in the range of 1–15 % of the total well/plate content of 
GLP-1 over a 2 h incubation period (Reimer et al.  2001 ; Anini and Brubaker  2003a ; 
Lim et al.  2009 ; Lauffer et al.  2009 ). Regarding the error in replicates of GLP-1 
secretion, these studies report standard error to be ~10 % (of the mean). 
 Some groups have examined the effect of similar treatments on GLP-1 secretion. 
Anini et al. found that the protein kinase C activator, phorbol 12-myristate 13- acetate 
(PMA) caused a 2.5-fold stimulation in GLP-1 secretion (Anini and Brubaker 
 2003a ), whereas Reimer et al. saw a 4.3-fold stimulation with the same dose and 
duration of incubation (Reimer et al.  2001 ). While both studies showed a robust 
stimulation of GLP-1 secretion, the difference in magnitude may be due to differ-
ences in media/buffers used during the secretion experiment or in sample preparation 
(both subjects of further discussion below). 
20.5  Relevance to the Human L-Cell In Vivo 
 Since NCI-H716 cells were derived from a human sample, they are of particular sig-
nifi cance to the study of human GLP-1 secretion. However, while these cells do secrete 
GLP-1 in response to nutrients, as found in vivo, it must be recognized that they are 
derived from a tumour cell which was likely to have been relatively undifferentiated 
initially. Furthermore, one study examined the ability of NCI-H716 cells to regulate 
expression of reporter plasmids encoding human and rat  proglucagon (i.e. the GLP-1 
prohormone gene). Surprisingly, no basal promoter activity was observed even in the 
presence of several positive regulators of rodent  proglucagon gene expression (Cao 
et al.  2003 ). In addition, compounds that are known to enhance  proglucagon gene 
expression in rodent models failed to stimulate the endogenous human  proglucagon 
gene in NCI-H716 cells. These fi ndings suggest that either the NCI-H716 cells do not 
regulate  proglucagon gene expression normally or that there are marked species-
specifi c differences in the regulation of  proglucagon expression. 
20.6  General Protocol 
20.6.1  Cell Maintenance Protocol 
 NCI-H716 cells are normally grown in suspension culture. Our group uses Roswell 
Park Memorial Institute (RPMI) media containing  L -glutamine and Phenol Red. 
This media is further supplemented to contain 10 % fetal bovine serum (FBS) and 
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100 units/ml each of penicillin and streptomycin (‘complete RPMI’). Cells can be 
grown in suspension in cell culture fl asks and should be kept at a density of ~500,000 
cells/ml to ensure a rapid growth rate; lower densities may cause stalled growth. 
Under these conditions, cells double every ~3 days and should be passaged once a 
week. To passage, cells do not require any enzymatic digestion; any small clumps 
of cells are simply dissociated using repeated serological pipetting. 
20.6.2  Experimental Protocol for Test Compounds 
 As NCI-H716 cells require a basement membrane matrix coating to attach to cell 
culture plates, preparation must occur before seeding cells for an experiment. Matrigel 
(BD Biosciences) is provided as a concentrate with lot-dependent concentration. It is 
stored frozen and gels at 15 °C. Matrigel is therefore thawed on ice (stock aliquots of 
the concentrate can be thawed overnight on ice in a 4 °C fridge, as per manufacturer’s 
directions). Plates or wells are then coated with 0.5 g/ml Matrigel diluted in ice-cold 
sterile Hanks Buffered Saline Solution (HBSS), with the area of the surface being 
coated dictating how much diluted Matrigel is required (generally ≥200 μl/well in a 
24-well plate, ≥ 800 μl/well in a 6-well plate, etc.). After allowing the Matrigel to gel 
for 1 h at room temperature, the plates/wells are then rinsed with HBSS and allowed 
to dry for 30 min; the surface is then ready for seeding of the cells. Cells should be 
reconstituted in complete RPMI to ~200,000 cells/ml (1 ml for each well in a 24-well 
plate, 2 ml for each in a 12-well plate, etc.). This density is optimized to allow ~2 days 
of growth before experimental treatments. On the day of treatment, cells are rinsed 
with low-serum RPMI media (i.e. 0.5 % FBS) then incubated with treatments in 
low-serum RPMI. For GLP-1 secretion studies, 2-h of incubation time is ideal as any 
possible effects on de novo GLP-1 synthesis are unlikely to be observed in this rela-
tively short time-frame. Over a 2-h incubation period, a 24-well plate treated with 
vehicle (control) will have ~300 pg of GLP-1 (total) per well in the collected media, 
with ~7,000 pg of GLP-1 in the cell lysate. Based on these values, the percent 
secretion (i.e. pg in media/(pg in media + cells) × 100) is 4.1 %. 
 Similar plating densities can be used for RNA and protein extraction experi-
ments. A larger surface area can be used for such studies (i.e. 6-well, 10-cm), 
depending on expression levels for the mRNA transcript or protein of interest. From 
a 6-well plate containing ~800,000 cell/well, ~20 μg of RNA and ~60 μg of protein 
can be collected. 
20.7  Assess Viability 
 To ensure treatments do not affect cell health or viability, standard tests should 
be employed. These tests include the 3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium (MTT) assay and neutral red uptake assay. Both of these tests 
can be done within a few hours of an experimental treatment, and should include a 
positive control, such as hydrogen peroxide, to ensure that the assay is reliable. 
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20.8  Experimental Readout 
 Sample processing from NCI-H716 cells is dependent on the nature of the experiment 
being conducted. Samples collected for GLP-1 secretion assay, as described in the 
experimental protocol above, are processed as follows. 
 Immediately after the 2-h incubation with treatments is complete, media is col-
lected and centrifuged for 5 min at 1,000× g and 4 °C to remove any fl oating cells. 
This media is then decanted into a new tube containing 1 % trifl uoroacetic acid 
(TFA) to make a fi nal TFA concentration of 0.1 %. This acidic environment pre-
vents protease activity and prepares the sample for the subsequent peptide purifi ca-
tion step. The culture plate with the cells is simultaneously placed on ice and then 
1 ml of ice-cold acidic cell lysis solution (i.e. 1 % TFA, 1 N hydrochloric acid, 5 % 
formic acid, and 1 % NaCl) is added. The cells are scraped and wells are rinsed with 
an additional volume of lysis buffer. These cell lysates are then sonicated, pelleted 
by centrifugation, and the supernatants collected on ice. However, of note, media 
and cells may be collected in a variety of different buffers, as indicated by the 
desired assay protocol, as long as proteolysis is prevented. 
 Depending on the method of hormone assay, samples may require additional 
purifi cation. Using a total GLP-1 radio-immuno assay (RIA; i.e. Millipore), we 
have found that additional purifi cation by C18 solid phase peptide extraction 
removes salts and proteases that may interfere with the assay. Peptides are thus 
 purifi ed using Sep Pak C18 Classic columns (Waters Associates) with 0.1 % TFA 
water (Solution A) and 0.1 % TFA/80 % isopropyl alcohol (Solution B), as follows: 
(1) 4 ml Solution B (wetting/clearing); (2) 4 ml Solution A (equilibrating); (3) sample 
loading; (4) 4 ml Solution A (washing); and (5) 4 ml Solution B (sample elution). 
A portion of the total 4 ml peptide eluate is then dried under vacuum in preparation 
for the RIA. Once samples have been purifi ed using this method, they can be sealed 
and stored at −20 °C for later analysis. 
 Media and cell GLP-1 content determined from the assay can be used to calculate 
percent GLP-1 secretion, as described above. These percent secretion values may differ 
slightly from 1 week to the next due to inter-assay variability. To control for differences 
in percent secretion, treatment groups are often normalized to a vehicle- treated control; 
as such, data often appears “relative to control” in papers examining GLP-1 secretion, 
although absolute values should always be included in the publication to facilitate 
comparison between studies. The use of an appropriate control in each experiment is 
critical. The control treatment group must thus contain the solvent in which the treat-
ment group is dissolved at an identical fi nal concentration. This may include dimethyl 
sulfoxide, ethanol or a buffer solution. In addition, experiments should also be designed 
to include a positive control for GLP-1 secretion. Strong activators of cAMP signaling, 
such as forskolin, have thus been used by several groups to demonstrate cell respon-
siveness to a known secretagogue in parallel with experimental treatment groups. 
 In GLP-1 secretion experiments with NCI-H716 cells, at least three biological 
replicates should be produced for each treatment and control group. Additionally, 
any given experiment should be repeated at least twice to ensure statistical power 
for subsequent analysis, thereby constituting a minimum of six replicates. 
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 For RNA and protein extraction, standard methods apply. For RT-PCR and 
 qRT-PCR studies, the target gene of interest should be determined relative to an 
internal control, such as 18S ribosomal RNA. However, quantifi cation of appropri-
ate reference genes for a particular treatment must also be done to ensure that the 
internal control does not change in response to the experimental treatment. Similarly, 
protein expression analysis by immunoblot should also include a suitable validated 
control, such as actin, for protein loading. 
20.9  Conclusions 
 The ability of the L-cell to respond to nutrient, hormonal and neurotransmitter cues 
is vital in the regulation of GLP-1 secretion and, ultimately, glucose homeostasis. 
Strategies targeting the GLP-1 system in humans have garnered great interest and 
application in the treatment of T2DM (Drucker  2011 ). Cell systems that enable a 
direct mechanistic examination of GLP-1 regulation have been and continue to be 
essential tools in developing novel GLP-1 therapies. The NCI-H716 cell line is the 
only human cell line currently available to study GLP-1. This places it in an impor-
tant position to relate the effects of various treatments to human biology, although 
experimental effects should always be cross-examined through the use of additional 
in vitro and in vivo models to strengthen the hypothesis. The NCI-H716 cells are 
thus a useful tool to study the control of GLP-1 release and the underlying cell 
signaling pathways as well as, potentially,  proglucagon gene expression. Overall, 
they are an excellent model to investigate the regulation of human GLP-1. 
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